GGHC
VRTX icon

Gilder Gagnon Howe & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,679
Closed -$814K – 258
2025
Q1 		$814K Sell
1,679
-28
-2% -$13K 0.01% 192
2024
Q4 		$687K Sell
1,707
-333
-16% -$154K 0.01% 226
2024
Q3 		$949K Sell
2,040
-27
-1% -$13K 0.01% 211
2024
Q2 		$969K Buy
2,067
+273
+15% +$118K 0.01% 207
2024
Q1 		$750K Sell
1,794
-20
-1% -$8.46K 0.01% 225
2023
Q4 		$738K Buy
+1,814
New +$670K 0.01% 216

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Gilder Gagnon Howe & Co's VRTX Position: Q2 2025 in Review

Gilder Gagnon Howe & Co sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 1,679 shares — an estimated $814K sold.

Gilder Gagnon Howe & Co first reported a position in VRTX in Q4 2023 and held it in 6 quarters. The position peaked at $969K in Q2 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Gilder Gagnon Howe & Co reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 1,679 Vertex Pharmaceuticals shares in Q2 2025, an estimated $814K.
  • Gilder Gagnon Howe & Co first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Gilder Gagnon Howe & Co's Vertex Pharmaceuticals position peaked at $969K in Q2 2024.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2025, filed 14 Aug 2025.